Researchers, investors and people who follow a disease closely all ask the same questions: which drugs are in development, who owns them, how far they have got and what comes next.
The answers sit in public trial registries and regulators. The tools that pull them together are built and priced for big pharma: tens of thousands a year, a sales call, and too bulky for someone who wants to follow a few areas. The other choice is days in the registries and a spreadsheet that is out of date a month later.
So we built OpenLandscape: every drug in development for a disease, target or company, read from the public sources every day.